A study looking at TNFR2 immunostaining intensity in ovarian tissues of 126 patients with ovarian cancer, found that the immunostaining intensity correlated with tumour stage (p < 0.001), stages I–II (30%) compared to stages III–IV (66%) [58]. This evidence concerns the gene TNFRSF1B and ovarian carcinoma.